☆ 4.4 Review

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis

GLOBAL HEART (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial

Patricia Palau et al.

Summary: This study evaluated the effect of dapagliflozin on maximal functional capacity in stable heart failure patients. The results showed that dapagliflozin significantly improved peak oxygen consumption at 1 and 3 months. The study suggests that dapagliflozin may have a positive impact on the health status of patients with heart failure with reduced ejection fraction.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. It is based on contemporary evidence and aims to improve quality of care and align with patients' interests.

JOURNAL OF CARDIAC FAILURE (2022)

Add to Collection

Article Medicine, General & Internal

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Muthiah Vaduganathan et al.

Summary: This study conducted a meta-analysis of the therapeutic effects of SGLT2 inhibitors in heart failure patients, showing that these drugs can significantly reduce the risk of cardiovascular death and hospitalization for heart failure in heart failure patients, demonstrating their importance in foundational treatment.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Editorial Material Medicine, Research & Experimental

An exploration of the experience of dapagliflozin in clinical practice

Anuba Paulvarnan Anitha et al.

Summary: This review focuses on the therapeutic aspects of dapagliflozin in clinical practice, suggesting that sodium-glucose cotransporters 2 inhibitors can significantly lower the disease burden associated with cardiovascular illness, with or without Type 2 diabetes mellitus.

FUTURE SCIENCE OA (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?

Steffen Pabel et al.

Summary: SGLT2 inhibitors have shown promising benefits in patients with heart failure, with various mechanisms potentially contributing to the improvement of HF status. Further translational studies are needed to fully understand the mechanisms of SGLT2 inhibitors in heart failure, but current evidence supports their use in both HFrEF and possibly HFpEF.

CURRENT HEART FAILURE REPORTS (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction

Hannah A. Blair

Summary: Dapagliflozin, an SGLT2 inhibitor approved for treating adults with symptomatic heart failure with reduced ejection fraction, significantly reduces the risk of heart failure worsening or cardiovascular death in patients with HFrEF, regardless of the presence of diabetes. The benefits of dapagliflozin are consistent across different background heart failure therapies.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

Dario Giugliano et al.

Summary: SGLT-2 inhibitors show a reduction in cardiovascular risk and renal efficacy in patients with cardiometabolic and renal diseases, leading to significant reductions in composite CV mortality or hospitalization for heart failure, heart failure, and renal outcomes.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif et al.

Summary: In a randomized trial, the SGLT2 inhibitor dapagliflozin significantly improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF) over a 12-week period, which can lead to an enhanced quality of life for these patients.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

John J. McMurray et al.

Summary: The study investigated the effects of dapagliflozin in chronic kidney disease patients with or without heart failure, showing that dapagliflozin reduced the risk of kidney failure, cardiovascular death/HF hospitalization, and prolonged survival in CKD patients independently of their history of heart failure.

JACC-HEART FAILURE (2021)

Add to Collection

Article Endocrinology & Metabolism

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Jagdeep S. S. Singh et al.

DIABETES CARE (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial

Michael E. Nassif et al.

CIRCULATION (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

Tsung-Ming Lee et al.

FREE RADICAL BIOLOGY AND MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Cardiac & Cardiovascular Systems

Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction

Robert J. Mentz et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

Add to Collection

Review Pharmacology & Pharmacy

Dapagliflozin efficacy and safety: a perspective review

Sarah L. Anderson

THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.